Personalis Q1 Revenue Plunges 25% to $15.47M, Net Loss Widens to $30.03M
Summary
Personalis, Inc. reported a challenging first quarter for 2026, with revenue declining 25% year-over-year to $15.47 million and net loss widening significantly to $30.03 million, resulting in a diluted loss per share of $0.29. While clinical diagnostic revenue saw robust growth of 365% due to Medicare coverage, this was offset by a 21% drop in pharma services revenue and planned reductions in VA MVP volumes. The overall weaker top-line performance and increased losses are material and could negatively impact investor sentiment. Traders will be closely watching for further details on the company's strategy to address the revenue decline in its pharma segment and improve overall profitability.
At the time of this announcement, PSNL was trading at $5.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $627M. The 52-week trading range was $3.84 to $11.50. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.